



VG Energy Appoints Two Veteran Businessmen with History of Successful Early Stage Investing to Board of Directors

SOURCE: Viral Genetics, Inc.

VG Energy Appoints Two Veteran Businessmen with History of Successful Early Stage Investing to Board of Directors, Michael Binnion and David Odell Bring Hands-on Business Development Experience to Accelerate Company's Implementation of Business Plan

Business Wire

San Marino, CA (PRWEB) August 31, 2011 VG Energy, a majority owned subsidiary of Viral Genetics, Inc. (Pinksheets:VRAL.pk), today announces that Michael Binnion and David Odell, savvy business veterans with successful experience in growing early stage companies, have come aboard as members of the Board of Directors. Seeking to utilize both the business acumen and the financial networking capabilities of these businessmen, the company is most fortunate that these gentlemen bring unique and complimentary skill sets that will accelerate the company's implementation of its business plan.

"We are very excited to have these two veteran businessmen join the VG Energy Board of Directors. Their expertise will move us forward quickly as we seek to monetize our technology," said Haig Keledjian, Viral Genetics' Chairman and CEO.

Mr. Michael Binnion, who has made a substantial investment in VG Energy, is a seasoned entrepreneur with a history of starting, financing and managing companies, primarily in the oil and gas sector. Currently the President and founding shareholder of Questerre Energy, a public oil and gas production company operating in Quebec, he was formerly President of CanArgo Energy, one of the first Western companies to engage in oil and gas exploration in the Republic of Georgia. CanArgo played an active role in helping introduce legislation and a regulatory framework for the oil and gas industry in the country. This experience in a nascent energy sector is expected to be brought to bear as VG Energy grows with the burgeoning algal biofuels sector.

An early shareholder who has invested significant capital in both Viral Genetics and VG Energy, Mr. David Odell brings hands-on business development skills to the board. As President & CEO at MedBridge, an ambulatory surgical center consortium, David leads the finance and partnership management function. In addition, he is Executive Vice President and Chief Financial Officer of TynanGroup, Inc. He has successfully managed TynanGroup's double-digit growth, leading to the firm's recognition by Inc. Magazine, in the recent past, as one of the fastest growing companies in America. Prior to TynanGroup, Mr. Odell was with a private accounting firm serving a broad spectrum of planning, audit, and tax clients. His success in medical business development will serve VG Energy as the company transitions from a development stage to a revenue producing company.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports, including statements about its VG Energy, Inc. subsidiary. None of Viral Genetics' drug compounds are approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world, nor are any non-pharmaceutical products of VG Energy, Inc. commercialized. While Viral Genetics believes that the forward-looking statements and underlying assumptions reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of any of its drug therapies in the treatment of any disease or health condition, the development of studies and strategies leading to

commercialization of those drug compounds in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, the successful outcome of such studies or tests, or the successful commercialization of VG Energy, Inc.'s non-pharmaceutical products. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.

Contact:

Viral Genetics, Inc.

Haig Keledjian, 626-334-5310

